ABBV
AbbVieNYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-05-08
As of May 8, 2026, ABBV has a composite score of 12.4 and a signal label of "mild favorable." This score is influenced by a medium confidence level of 75.5 and a low risk label, with notable drivers including macro factors related to labor, rates, growth, and inflation. The guidance credibility is high at 100.0, indicating strong trust in the management's forecasts. The analysis is provisional, reflecting the current state of the inputs.
Price
Daily closes from AlphaVantage. Earnings/event dots are placed inline.
Factor signals
Read top-to-bottom: thesis (is this a strong company over a 1–3 year hold), watch flags (has something changed worth re-reading), and position context (how violent might the path be). Each pill is a parallel diagnostic — never aggregated into a single score.
Thesis
— is this a strong company over a 1–3 year hold?Why this rank
- Direction share0.91
- Slope (norm)-0.51
- Bonus0.00
Why this rank
Trailing four: 2024-Q3, 2025-Q1, 2025-Q2, 2025-Q3
Why this rank
Watch
— has something changed worth re-reading?Why this setup
EPS estimate $3.78 → $3.76 (-0.4% / 30d). 6 raised, 10 cut, 21 covering analysts.
0 upgrades, 0 downgrades / 30d, 7 maintained. 73% of analysts rate Buy.
4 PT revisions / 30d. Avg target 31.2% above current price.
0 positive, 1 negative / 30d. See F4 management tile for the event list.
F4 · Management deep-dive — recent events, stated priorities, guidance track record
Recent 8-K events
11 material events in the last 24 months — top 5 listed below.
Stated priorities
3 priorityies extracted from earnings transcripts (as of 2026-05-08).
- 1.Increase EPS guidancegrowthbehind4% progress
4/29: “Raises 2026 Adjusted Diluted EPS Guidance Range from $13.96 - $14.16 to $14.08 - $14.28.”
Why this status
Stated in 3 of last 3 quarters. EPS guidance was raised from $13.96-$14.16 to $14.08-$14.28 for 2026. Despite the earnings miss in 2026-Q1, the guidance increase suggests confidence in future performance, but delivery remains to be seen.
- 2.Announce share buybackcapital allocationmixed34% progress
2/26: “AbbVie announced a share buyback program on February 24, 2026.”
Why this status
Newly stated in 2026-Q1. AbbVie announced a share buyback program in February 2026. However, the financials do not yet reflect any buyback activity, indicating limited progress on this priority.
- 3.Debt issuance for capitalcapital allocationmixed34% progress
3/4: “Completed a $750M debt issuance on March 4, 2026.”
Why this status
Newly stated in 2026-Q1. AbbVie completed a $750M debt issuance in March 2026 to raise capital. This aligns with their capital allocation strategy, but the impact on financials is not yet visible.
Guidance track record
Last 8 quarters of EPS guidance with actuals.
Per-quarter detail
| Period | Guidance | Actual | Result |
|---|---|---|---|
| 2024-03-31 | $2.18 – $2.22 | $2.31 | beat |
| 2024-06-30 | $2.53 – $2.57 | $2.65 | beat |
| 2024-09-30 | $2.88 – $2.92 | $3.00 | beat |
| 2025-03-31 | $2.34 – $2.38 | $2.46 | beat |
| 2025-06-30 | $2.84 – $2.88 | $2.97 | beat |
| 2025-09-30 | $1.74 – $1.78 | $1.86 | beat |
| 2025-12-31 | $2.61 – $2.65 | $2.71 | beat |
| 2026-03-31 | $2.56 – $2.60 | $2.65 | beat |
Beat / inside / miss is computed from the guided range when issued; for point-estimate quarters a ±5% tolerance band around the mid is used. surprise_pct_vs_mid is unstable when guided EPS is near zero, so it is not surfaced as a headline.
Position context
— how violent might the path be while I hold it?Why this risk level
Recent vol — 30d annualized 26%; 252d 25%.
Drawdown — Max 1y −17%. Bad day move −2%.
Beta to sector ETF (XLV) — 0.94 over 1y.
Liquidity — score 100/100.
Sub-scores — vol 59/100, drawdown 65/100, beta 94/100, earnings vol —.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive — historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only — describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-05-08.
What changed
The most important moves since the prior daily snapshot.
- No material changes since the prior snapshot.
No material changes since the prior snapshot.
as of 2026-05-08
Management scorecard
How management runs the business — capital, margins, balance sheet, and how reliably they guide and deliver.
Met or beat guidance 100% of the last 8 guided quarters · 4.0% avg surprise
What management is focused on
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
- #1
Increase EPS guidance
GrowthNew since 2026-05-04AbbVie aims to increase its EPS guidance for the fiscal year 2026.
BehindStated in 3 of last 3 quarters. EPS guidance was raised from $13.96-$14.16 to $14.08-$14.28 for 2026. Despite the earnings miss in 2026-Q1, the guidance increase suggests confidence in future performance, but delivery remains to be seen.
4%CEO/CFO:“Raises 2026 Adjusted Diluted EPS Guidance Range from $13.96 - $14.16 to $14.08 - $14.28.”Press releaseSource dated 2026-04-29Stated 3 of last 8 quartersFirst seen 2026-05-04Show history (3)
- 2026-Q2Press release
“Raises 2026 Adjusted Diluted EPS Guidance Range from $13.96 - $14.16 to $14.08 - $14.28.”
- 2026-Q1Press release
“Provides 2026 Adjusted Diluted EPS Guidance Range of $14.37 to $14.57.”
- 2025-Q4Press release
“Provides 2026 Adjusted Diluted EPS Guidance Range of $14.37 to $14.57.”
- #2
Announce share buyback
Capital allocationNew since 2026-05-04AbbVie announced a share buyback program to return capital to shareholders.
Behind →MixedNewly stated in 2026-Q1. AbbVie announced a share buyback program in February 2026. However, the financials do not yet reflect any buyback activity, indicating limited progress on this priority.
34%CEO/CFO:“AbbVie announced a share buyback program on February 24, 2026.”Multiple sourcesSource dated 2026-02-26Stated 1 of last 8 quartersFirst seen 2026-05-04Show history (1)
- 2026-Q1Multiple sources
“AbbVie announced a share buyback program on February 24, 2026.”
- #3
Debt issuance for capital
Capital allocationNew since 2026-05-04AbbVie issued debt to raise capital for strategic initiatives.
Behind →MixedNewly stated in 2026-Q1. AbbVie completed a $750M debt issuance in March 2026 to raise capital. This aligns with their capital allocation strategy, but the impact on financials is not yet visible.
34%CEO/CFO:“Completed a $750M debt issuance on March 4, 2026.”Multiple sourcesSource dated 2026-03-04Stated 1 of last 8 quartersFirst seen 2026-05-04Show history (1)
- 2026-Q1Multiple sources
“Completed a $750M debt issuance on March 4, 2026.”
How this stock is priced
Two ways to read price: against peers in the same business, and against the company's own history.
Looks more expensive than peers.
Cheaper than its own typical valuation.
P/E over the last 5 years
68 monthly pointsHow this compares
A side-by-side read on composite, valuation, and risk versus peers.
| Stock | Composite | Valuation | Risk |
|---|---|---|---|
ABBV AbbVie | +12 | fair | low |
LLY Lilly (Eli) | +21 | full | moderate |
JNJ Johnson & Johnson | +18 | full | low |
UNH UnitedHealth Group | +24 | fair | elevated |
MRK Merck & Co. | +28 | full | moderate |
Risk — how this stock moves
What a normal day looks like, what a bad day looks like, and the worst the last year has thrown at it.
What could change this view
Conditional scenarios — if X happens, the score would shift by about Y points. These are not predictions.
- If health_care sector trend rises from +0.06 into 'improving' (>= +0.20)+5.0 pts
- If next-quarter guidance is cut (currently RAISED as of 2026-04-29)-16 pts
- If labor state reverses from -0.31 (negative) to +0.31 (positive)-6.8 pts
- If health_care sector trend falls from +0.06 into 'weakening' (<= -0.20)-5.0 pts
- If rates state reverses from -0.37 (negative) to +0.37 (positive)-2.9 pts
Material updates
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
- 2026-04-2910d agoItem 2.02
. 104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ABBVIE INC. Date: April 29, 2026 By: /s/ Scott T. Reents Scott T. Reents Executive Vice President, Chief Financial Officer
earnings preannouncementnegativescore 63 - 2026-04-031mo agoItem 2.02
Results of Operations and Financial Condition Reported GAAP earnings and adjusted non-GAAP earnings for the first quarter of 2026 are expected to include acquired IPR&D and milestones expense of $744 million on a pre-tax basis, representing an unfavorable impact of $0.41 to both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share. Results for the quarter ended March 31, 2026 have not been finalized and are subject to our financial statement closing procedures. The…
earnings preannouncementnegativescore 35 - 2026-03-042mo agoItem 8.01
Other Events. On March 4, 2026, AbbVie Inc. (“ AbbVie ”) completed its previously announced underwritten public offering (the “ Notes Offering ”) of $750,000,000 aggregate principal amount of its senior floating rate notes due 2028 (the “ Floating Rate Notes ”), $1,500,000,000 aggregate principal amount of its 3.775% senior notes due 2028 (the “ 2028 Notes ”), $1,250,000,000 aggregate principal amount of its 4.125% senior notes due 2031 (the “ 2031 Notes ”), $1,250,000,000 aggregate principal…
capital allocationneutralscore 12 - 2026-02-262mo agoItem 8.01
Other Events. On February 24, 2026, AbbVie Inc. (“ AbbVie ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with J.P. Morgan Securities LLC, BofA Securities, Inc., Morgan Stanley & Co. LLC and Wells Fargo Securities, LLC, acting for themselves and as representatives of the several underwriters named in Schedule II therein (collectively, the “ Underwriters ”), pursuant to which AbbVie agreed to issue and sell to the Underwriters $750,000,000 aggregate principal amount…
capital allocationpositivescore 10 - 2026-02-043mo agoItem 2.02
. 104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ABBVIE INC. Date: February 4, 2026 By: /s/ Scott T. Reents Scott T. Reents Executive Vice President, Chief Financial Officer
earnings preannouncementnegativescore 9
Score history
The composite score, snapshot by snapshot. The dotted line at zero separates leaning-positive from leaning-negative.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.